Custom Assays

Our technology platform fully integrates DNA collection, extraction and analysis, with an intuitive interface that is easy to operate.

We're taking what we've learned through thirteen years of research and development and applying it to new diverse fields such as environmental testing, veterinary diagnostics, and food testing.

Using Spartan's technology, end users receive test results in a fraction of the time compared to traditional lab-based testing. It's on-site, lab quality DNA testing in the palm of your hand.

Do you have a problem that needs a Spartan solution?

Evidence

Accuracy and precision of Legionella isolation by US laboratories in the ELITE program pilot study

Environmental
  • The CDC conducted a proficiency study of 20 ELITE-certified Legionella culture testing labs.
  • On average, the culture labs undercounted actual Legionella concentrations by 17-fold and values differed between labs by 6-fold.
Read the full study

Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention

Medical
  • Spartan's rapid CYP2C19 genotyping test was implemented at the University of Pennsylvania Health System for patients receiving percutaneous coronary intervention (PCI)
  • 28% of patients carried loss-of-function CYP2C19 mutations
  • Prasugrel or ticagrelor were used in 30% of the genotyped group vs. 21% of the usual care group who were not genotyped
Read the full study

Precision Medicine at the University of Alabama at Birmingham: Laying the foundational processes through implementation of Genotype-Guided Antiplatelet Therapy

Medical
  • This independent report describes concordance of the Spartan RX with gold standard genotyping.

The use described in this publication is not approved or cleared by the US FDA. This study was supported in part by University of Alabama at Birmingham's Health Service Foundations' General Endowment Fund; The Hugh Kaul Precision Medicine Institute; by grants from the National Institutes of Health (grant numbers RO1HL092173, K24HL133373 to N.L.); and the National Human Genome Research Institute of the National Institutes of Health (grant number T32HG008961 to B.D.). Spartan knows of no other financial interests. Spartan knows of no significant risks or safety concerns associated with the use described in this publication.

Read the full study
View all evidence